RS50790B - Korišćenje derivata piridoindolona za spravljanje lekova - Google Patents

Korišćenje derivata piridoindolona za spravljanje lekova

Info

Publication number
RS50790B
RS50790B YUP-834/03A YUP83403A RS50790B RS 50790 B RS50790 B RS 50790B YU P83403 A YUP83403 A YU P83403A RS 50790 B RS50790 B RS 50790B
Authority
RS
Serbia
Prior art keywords
methyl
group
hydrogen
formula
ethyl group
Prior art date
Application number
YUP-834/03A
Other languages
English (en)
Serbian (sr)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of YU83403A publication Critical patent/YU83403A/sh
Publication of RS50790B publication Critical patent/RS50790B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YUP-834/03A 2001-04-27 2002-04-26 Korišćenje derivata piridoindolona za spravljanje lekova RS50790B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (2)

Publication Number Publication Date
YU83403A YU83403A (sh) 2006-08-17
RS50790B true RS50790B (sr) 2010-08-31

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-834/03A RS50790B (sr) 2001-04-27 2002-04-26 Korišćenje derivata piridoindolona za spravljanje lekova
YUP-839/03A RS50791B (sr) 2001-04-27 2002-04-26 Farmaceutske kombinacije zasnovane na derivatima piridoindolona

Family Applications After (1)

Application Number Title Priority Date Filing Date
YUP-839/03A RS50791B (sr) 2001-04-27 2002-04-26 Farmaceutske kombinacije zasnovane na derivatima piridoindolona

Country Status (33)

Country Link
US (3) US7524857B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004528343A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2443012C (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ299465B6 (enExample)
DE (2) DE60208365T2 (enExample)
DK (2) DK1385512T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400744A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034787L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385513E (enExample)
RS (2) RS50790B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087574A2 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CN1240382C (zh) 2006-02-08
DK1385513T3 (da) 2007-01-15
RU2003130376A (ru) 2005-04-10
CN1505511A (zh) 2004-06-16
CZ20032910A3 (en) 2004-07-14
US6967203B2 (en) 2005-11-22
CZ295224B6 (cs) 2005-06-15
CY1105813T1 (el) 2011-02-02
ZA200307785B (en) 2004-10-06
DE60208365D1 (de) 2006-02-02
US7160895B2 (en) 2007-01-09
EP1385513A1 (fr) 2004-02-04
EP1385512B1 (fr) 2005-12-28
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
CA2444334A1 (fr) 2002-11-07
JP2004528343A (ja) 2004-09-16
DK1385512T3 (da) 2006-05-22
PL366916A1 (en) 2005-02-07
FR2823975A1 (fr) 2002-10-31
US20040122027A1 (en) 2004-06-24
CN1505510A (zh) 2004-06-16
IL158312A0 (en) 2004-05-12
MXPA03009639A (es) 2004-06-30
NO20034785D0 (no) 2003-10-24
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
PT1385512E (pt) 2006-05-31
AR034313A1 (es) 2004-02-18
NZ528671A (en) 2004-06-25
BG108260A (bg) 2004-12-30
ATE314070T1 (de) 2006-01-15
PT1385513E (pt) 2007-01-31
CA2443012A1 (en) 2002-11-07
UA74876C2 (en) 2006-02-15
YU83403A (sh) 2006-08-17
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
KR20040015138A (ko) 2004-02-18
NO20034787L (no) 2003-12-23
EE200300465A (et) 2003-12-15
IL158266A0 (en) 2004-05-12
EP1385513B1 (fr) 2006-09-06
WO2002087575A1 (fr) 2002-11-07
US20050272760A1 (en) 2005-12-08
CA2443012C (fr) 2009-07-28
IS2441B (is) 2008-11-15
HK1060066A1 (en) 2004-07-30
SK13242003A3 (sk) 2004-03-02
HUP0400744A2 (hu) 2004-06-28
YU83903A (sh) 2006-08-17
RU2292888C2 (ru) 2007-02-10
US20040122036A1 (en) 2004-06-24
SK13252003A3 (sk) 2004-03-02
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
BR0209138A (pt) 2004-06-08
CZ20032909A3 (en) 2004-06-16
IS6984A (is) 2003-10-09
DE60214533T2 (de) 2007-06-21
WO2002087574A3 (fr) 2003-02-13
ES2271264T3 (es) 2007-04-16
HK1059895A1 (en) 2004-07-23
JP2004531538A (ja) 2004-10-14
DE60208365T2 (de) 2006-09-07
RS50791B (sr) 2010-08-31
HUP0400745A2 (hu) 2004-08-30
NO20034787D0 (no) 2003-10-24
KR100847413B1 (ko) 2008-07-18
US7524857B2 (en) 2009-04-28
ES2254683T3 (es) 2006-06-16
CZ299465B6 (cs) 2008-08-06
IL158312A (en) 2009-09-01
EE200300466A (et) 2003-12-15
PL366910A1 (en) 2005-02-07
DE60214533D1 (de) 2006-10-19
IL158266A (en) 2009-09-01
EA005930B1 (ru) 2005-08-25
EA200301062A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
NZ522246A (en) 2-acyl indole derivatives and their use as antitumor agents
CN107260743B (zh) 氮杂色胺酮衍生物作为ido1和/或tdo抑制剂的用途
WO2021218965A1 (zh) 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
RS50790B (sr) Korišćenje derivata piridoindolona za spravljanje lekova
Feng et al. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022)
EP1442015A1 (de) VERWENDUNG VON 2−ACYLINDOLEN ZUR BEHANDLUNG VON TUMOREN
CN111821303A (zh) 沃替西汀及其盐在制备抗肿瘤药物中的应用
WO2024156250A1 (zh) 7-羰基星孢菌素衍生物及其制备方法和应用
HK1059895B (en) Use of pyridoindolone derivatives for preparing anticancer medicines
JPH03502806A (ja) ガンの処理